Erik Harris - 01 Mar 2026 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
01 Mar 2026
Net transactions value
-$240,289
Form type
4
Filing time
03 Mar 2026, 19:08:17 UTC
Previous filing
21 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Harris Erik EVP & Chief Commercial Officer 60 LEVERONI COURT, NOVATO /s/ Karah Parschauer, attorney-in-fact 03 Mar 2026 0001780113

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +11,643 +13% $0.000000 99,498 01 Mar 2026 Direct F1
transaction RARE Common Stock Sale $240,289 -10,539 -11% $22.80 89,515 02 Mar 2026 Direct F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics.
F2 Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
F4 Includes a total of 556 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025 and October 31, 2025.
F5 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.